###### Strengths and limitations of this study

-   Being a retrospective study, this study shares the limitations of secondary data collection; as a result, we were unable to find some predictors like viral load, alcohol consumption, smoking and nutritional history.

-   The study is not based only on patient cards that started the second-line antiretroviral therapy at the same point in time; also the length of the follow-up period for each participant was not equal across all participants.

-   The method of data anaysis ensures a valid estimate by handling data that are measured at different time periods and has missing values.

-   The large number of measurements will again strengthen the precision of the estimates.

Background {#s1}
==========

HIV has continued to be a major global public health problem, having killed more than 35 million lives so far. In 2017, 940 000 people died from HIV-related causes globally.[@R1] According to the Ethiopia Demographic and Health Survey of 2016, the adult prevalence of HIV in Ethiopia was 0.9%.[@R2] Death due to HIV/AIDS has enormously decreased due to the introduction of antiretroviral therapy (ART) and millions of people are currently accessing it.[@R3]

The body weight of patients with HIV has been an important diagnostic and evaluation measure. Low body mass index (BMI) is recognised as one of the first criteria for the clinical definition of AIDS. The current WHO clinical staging of the disease also includes moderate unexplained weight loss (\<10% presumed or measured body weight, stage 2), unexplained severe weight loss (\>10% of body weight or BMI [\<]{.ul}18.5 kg/m^2^, clinical stage 3) and HIV wasting syndrome (unexplained severe wasting, clinical stage 4) as criteria to define advanced HIV infection.[@R4]

The BMI of patients with HIV is an important predictor of ART outcome,[@R5] including the prediction of the CD4 cells change[@R9] and death.[@R10] A negative change in BMI of patients was also found to be an independent predictor of dropout from HIV care.[@R13]

The BMI of patients with HIV is affected by gender,[@R14] duration of treatment,[@R10] isoniazid prophylaxis therapy (IPT) and cotrimoxazole prophylaxis therapy (CPT),[@R17] WHO stage[@R14] and CD4 count.[@R15]

This study focused on patients on second-line ART mainly because there is no much option for physicians to choose from if this therapy fails. BMI evolution is a very important and easily calculable tool that can predict treatment outcome, dropout from treatment, CD4 recovery and death, but literature about its evolution across treatment time and factors affecting it is limited. Therefore this study tried to fill this information gap by determining the BMI evolution over treatment time and identifying the key factors affecting it. The information generated by this study will contribute to monitoring the response of patients for ART.

Method and materials {#s2}
====================

Study design and period {#s2-1}
-----------------------

An institution-based retrospective follow-up study was conducted among adults, aged 24 years and above, who started second-line ART from February 2008 to February 2016

Study area and population {#s2-2}
-------------------------

The study was conducted in Amhara regional state which is one of the nine administrative regions and two city councils of Ethiopia. The region constitutes majority of ART users in the country. The study population was adult HIV-infected patients on second-line ART in all the nine referral hospitals of the region. The first-line treatment consisted of a combination of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) with one non-nucleoside reverse transcriptase inhibitor. In case of failure of first-line treatment, a second-line treatment was implemented, using two NRTIs not previously used in first-line treatment, as well as one additional protease inhibitor.

Sample size and sampling procedure {#s2-3}
----------------------------------

All patients with HIV who initiated second-line therapy (n=1233) between February 2008 and 2016 were included. But only 1016 patients who had two or more measurements of weight were included in the study.

Data collection procedures {#s2-4}
--------------------------

A data extraction checklist was prepared and the data were collected from registration cards of patients with HIV. Data about the baseline weight and height of patients and other factors like sociodemographic, clinical and treatment related factors were also collected from the registration card of each patient with HIV. Adherence to ART was assessed by pill counts at visits and was recorded as 'GOOD' (≥95% adherence), 'FAIR' (80%--95% adherence) or 'POOR' (\<80% adherence).[@R20]

Data structure, compilation and analysis strategy {#s2-5}
-------------------------------------------------

The data were cleaned and entered into EPI info V.7 and analysed using STATA V.14.0. The BMI of patients with HIV was computed by dividing the weight of patients in kilograms (kg) that was recorded during each follow-up visit, by their baseline height in metre squared. Exploratory data analysis for the weight of patients including individual profile plot, mean profile plot, and descriptive and summary statistics were done. To determine the factors associated with BMI of patients, bivariable analysis for each independent variable was assessed and those found to be significant (p\<0.25) were selected for the multivariable analysis. The need for random intercept and random slope was checked by the likelihood ratio (LR) test. Since we cannot ignore the repeated measurements that have between-individual variation and within-individual variation,[@R21] a linear mixed-effect model with random intercept and random slope was fitted.

Patient and public involvement {#s2-6}
------------------------------

Since we have used secondary data/chart review, patients or the public were not involved during identifying the research question or the design and conduct of the study.

Results {#s3}
=======

Patient characteristics {#s3-1}
-----------------------

We had a total of 1016 adult patients who were taking second-line ART. Of the total, 538 (52.95%) were male. All participants were 24 years of age or older with a median age of 33 years (IQR: 28; 39). A large proportion of these patients, 370 (37.1%), was unemployed and 371 (36.9%) had attended secondary school.

The median follow-up time was 18 months (IQR: 5.2; 32.2). There were a maximum of 12 and a minimum of 2 measurements of weight per patient. Almost all visits were not balanced in their time of measurements. The median time between each weight measurement is reported as median (IQR) as follows: 6.7 (4.27, 10.03), 6.08 (4.14, 9), 6.13 (4.2, 8.9), 6.27 (4.53, 8.9), 5.9 (3.97, 7.79), 5.83 (3.7, 8.13), 5.45 (3.37, 7.43), 4.86 (2.97, 6.2), 5.19 (3, 7.37), 5.97 (4.23, 7.04), 5.55 (2.83, 5.86) and 3 (0.9, 4.84) months from the first to the twelfth weight measurement, respectively.

At the initiation of second-line ART majority of the participants, 393 (45.54%), were at WHO stage I and 324 (37.54%) were at WHO stage III. A large proportion of the participants, 871 (86%), had working functional status at baseline, the rest, 114 (11.25%) and 28 (2.75%), were ambulatory and bedridden, respectively. The median CD4 count was 253 (IQR: 147; 399). IPT and CPT were given for 247 (24.87%) and 256 (25.65%) participants, respectively ([table 1](#T1){ref-type="table"}).

###### 

Baseline sociodemographic and baseline characteristics of adult patients with HIV on ART in Amhara region, 2008--2016

  Variables              Frequency   Percentage
  ---------------------- ----------- ------------
  Age, years                         
   25--34                547         53.89
   35--44                333         32.81
   45--54                104         10.25
   55--64                26          2.56
   \>65                  6           0.59
  Sex                                
   Female                478         47.05
   Male                  538         52.95
  Educational status                 
   No education          315         31.34
   Primary education     201         20.00
   Secondary education   371         36.92
   Tertiary education    118         11.74
   Missing               11          0.01
  Occupation                         
   Unemployed            370         36.42
   Governmental          286         28.15
   Non-governmental      21          2.06
   Private               66          6.50
   Daily labourers       254         25.00
   Missing               19          1.87
  WHO stages                         
   Stage I               393         45.54
   Stage II              66          7.65
   Stage III             324         37.54
   Stage IV              80          9.27
  Functional status                  
   Working               871         86
   Ambulatory            114         11.25
   Bedridden             28          2.75
  CPT given                          
   No                    742         74.35
   Yes                   256         25.65
  INH given                          
   No                    746         75.13
   Yes                   247         24.87

ART, antiretroviral therapy; CPT, cotrimoxazole prophylaxis therapy; INH, isoniazid.

Exploratory data analysis {#s4}
=========================

At baseline a total of 391 (38.5%) patients had BMI \<18.5 kg/m^2^ whereas 549 (54%), 64 (6.3%) and 12 (1.2%) had BMI 18.5--24.9 kg/m^2^, 25--29.9 kg/m^2^ and [\>]{.ul}30 kg/m^2^, respectively.

Individual profile {#s4-1}
------------------

The average BMI of patients at baseline was 19.03 kg/m^2^ (SD=3.6 kg/m^2^). The minimum and maximum BMIs were 8.33 kg/m^2^ and 33.59 kg/m^2^, respectively. Before proceeding to the formal statistical analysis we have described the data by exploring how individuals' BMIs change over time. To make the individual profile plot more informative and understandable, we have prepared it for the first 100 individuals ([figure 1](#F1){ref-type="fig"}).

![Individual profile plot of body mass index (BMI) over time for the first 100 individuals on second-line antiretroviral therapy (ART) in Amhara region, 2008--2016](bmjopen-2019-033393f01){#F1}

As we can see from this plot, the BMI status of patients has high variability within an individual over time and among individuals at baseline and also through time. Therefore to fit the data which have variability in the intercept and slope of trajectories very well, we have used a mixed model.

Exploring the mean profile {#s4-2}
--------------------------

As stated above, all measurements in the data have no similar time of measurements, therefore, we have used locally weighted scatterplot smoothing (LOWESS) to determine BMI evolution over time ([figure 2](#F2){ref-type="fig"}).

![Time plot of body mass index (BMI) versus treatment time in months with LOWESS smoothed curve superimposed for patients with HIV on second-line antiretroviral therapy (ART) in Amhara region, 2008--2016.](bmjopen-2019-033393f02){#F2}

As one can easily understand from the mean profile plot, the BMI of these patients showed a linear increment over the treatment time.

Modelling the BMI {#s4-3}
-----------------

### Correlation structure checking and model comparison {#s4-3-1}

Comparing with Akaike information criteria (AIC), the correlation structure with the lowest AIC was chosen, in this case the unstructured correlation structure ([table 2](#T2){ref-type="table"}).

###### 

Correlation structure checking and model comparison

        Unstructured   Identity    Exchangeable
  ----- -------------- ----------- --------------
  AIC   14 337.93      17 775.34   17 666.17
  BIC   14 531.08      17 956.02   17 853.09

AIC, Akaike Information Criteria; BIC, Bayesian Information criteria.

The need for random slope and intercept was checked by the likelihood ratio test of a model without a random intercept, a model with only random intercept and a model with both random intercept and slope ([table 3](#T3){ref-type="table"}).

###### 

Comparison of random effects models

  Random effects            LR χ^2^   P value
  ------------------------- --------- ---------
  Model 1 intercept         5625.28   0.0000
  Model 2 intercept, time   297.13    0.0000

So as we can see from the [table 3](#T3){ref-type="table"} the inclusion of random intercept and random slope is reasonable, so in the final model we have used both random intercept and random slope.

Factors affecting BMI evolution over time {#s4-4}
-----------------------------------------

Based on the multivariable linear mixed-effects regression output: time since the start of second-line ART, IPT, CPT, functional status, WHO stage of the disease; and time interaction of categorical variables like educational status, functional status and WHO stages were found to be significant predictors of the BMI evolution of patients with HIV on second-line ART.

Keeping all the other variables constant, for a 1-month increment in treatment duration, the BMI of a patient increases by 0.013 kg/m^2^. But specifically individuals who have tertiary level of education, ambulatory functional status and who are at WHO stage III have additional 0.02 kg/m^2^, 0.03 kg/m^2^ and 0.01 kg/m^2^ increment, respectively, in their BMI for a 1-month increment in the duration of treatment.

Taking IPT and CPT increases BMI by 0.87 kg/m^2^ and 0.63 kg/m^2^, respectively, as compared with their counterparts. Non-governmental organisation employment was associated with a 2.02 kg/m^2^ increment when compared with government employment. Patients who are ambulatory and bedridden in their functional status have a 1.16 kg/m^2^ and 1.83 kg/m^2^ decrement in their BMI, respectively, as compared with those who have working functional status. Patients who are at WHO stage III and WHO stage IV have decreased BMI by 0.42 kg/m^2^ and 0.62 kg/m^2^, respectively, when compared with those who are at WHO stage I. For a unit cell/mm^3^ increase in the CD4 count of patients BMI was found to increase by a factor of 0.001 kg/m^2^ ([table 4](#T4){ref-type="table"}).

###### 

Parameter estimates for full linear mixed-effects model

  ------------------------------------------------------------------------
  Characteristics            Coefficient   CI\           P value   
                                           Lower Upper             
  -------------------------- ------------- ------------- --------- -------
  Intercept                  19.03         18.11         19.95     0.000

  Sex                                                              

  Female                     0.00                                  

  Male                       −0.01         −0.51         0.48      0.956

  Adherence                                                        

  Poor                       0.00                                  

  Fair                       0.43          −0.24         1.10      0.207

  Good                       0.48          −0.06         1.02      0.080

  INH prophylaxis given                                            

  No                         0.00                                  

  Yes                        0.87          0.32          1.42      0.002

  CPT prophylaxis given                                            

  No                         0.00                                  

  Yes                        0.63          0.08          1.19      0.025

  Educational status                                               

  Illiterate                 0.00                                  

  Primary                    −0.03         −0.72         0.66      0.924

  Secondary                  0.47          −0.21         1.14      0.176

  Tertiary                   0.94          −0.01         1.89      0.051

  Functional status                                                

  Working                    0.00                                  

  Ambulatory                 −1.16         −1.95         −1.31     0.000

  Bedridden                  −1.83         −2.47         −1.21     0.000

  WHO stage                                                        

  Stage I                    0.00                                  

  Stage II                   −0.06         −0.45         0.33      0.760

  Stage III                  −0.42         −0.65         −0.20     0.000

  Stage IV                   −0.62         −1.02         −0.22     0.002

  CD4 count                  0.001         0.0008        0.0015    0.000

  Time on treatment          0.013         0.004         0.022     0.005

  Education status × time                                          

  Illiterate × time          0.00                                  

  Primary × time             0.002         −0.01         0.015     0.801

  Secondary × time           0.01          −0.003        0.019     0.162

  Tertiary × time            0.02          0.01          0.04      0.009

  Functional status × time                                         

  Working × time             0.00                                  

  Ambulatory × time          0.03          0.01          0.05      0.000

  Bedridden × time           −0.01         −0.05         0.02      0.49

  WHO stage × time                                                 

  Stage I × time             0.00                                  

  Stage II × time            0.004         −0.008        0.166     0.522

  Stage III × time           0.01          0.007         0.020     0.000

  Stage IV × time            −0.0003       −0.016        0.016     0.969
  ------------------------------------------------------------------------

CPT, cotrimoxazole prophylaxis; INH, isoniazid.

Discussion {#s5}
==========

This study has found a linear increment in BMI of patients over the duration of the treatment. There were BMI differences between subjects at baseline and during their progress over time.

Factors found to have a significant effect on the evolution of BMI over treatment time at a multivariable linear mixed-effects model were, second-line treatment duration, IPT, CPT, employment status, functional status of the patient, WHO stage and CD4 count. Time interaction of educational status, functional status and WHO stage were also significant predictors of BMI evolution.

For a 1-month increase in treatment duration the BMI of patients increases by 0.04 kg/m^2^; this finding is in line with studies in South Africa,[@R22] India[@R10] and USA.[@R23] The weight gain could possibly be due to normal reversion of the weight loss associated with HIV or due to drug-related metabolic changes which include hyperlipidaemia, insulin resistance and diabetes.[@R24]

Patients who took IPT and CPT have increased BMI when compared with their respective counterparts. This finding is supported by other studies like a study conducted in Abidjan[@R17] and multicentre controlled clinical trial in Africa.[@R18] The main reason for this association could be the reduction of potentially disabling and wasting diseases like tuberculosis and other opportunistic infections by these prophylactic drugs.[@R25] Highly increased appetite by the prophylaxis could also be a possible explanation.[@R27]

Being ambulatory and bedridden decreases BMI when compared with those who are working. Since these individuals are not working they may not access a nutritious and balanced diet which affects their BMI. Another reason could be additionally decreased immunity caused by physical inactivity which makes them more susceptible to minor infections leading to higher calorie loss.[@R28] These groups of people are also at a higher risk of diarrhoeal disease for they cannot take care of themselves which in turn causes weight loss.[@R29]

When compared with patients at WHO stage I, those at WHO stages III and IV have decreased BMI. This finding is in line with a multicentre study in resource-limited settings which shows individuals who had high clinical status (WHO stages III and IV) had poorer weight gain when compared with weight change in patients at lower WHO stage.[@R14] The possible reason can be unexplained chronic diarrhoea and HIV enteropathy in these patients and the associated malabsorption[@R4] or it could be due to fever of unknown origin in the late stage of the disease which results in an increased calorie loss and wasting.[@R30]

The BMI of patients was also found to increase with the increment in their CD4 count. This positive association is supported by evidence from a study conducted in Boston[@R15] and Tanzania.[@R19] This increment can be explained by the association of increment of CD4 count with good clinical changes like viral suppression, improved immunity and appetite, leading to increment in the BMI of patients.[@R13]

Being a retrospective study, this study has limitations of secondary data collection, as a result, we were unable to find some predictors like viral load, alcohol consumption, smoking, marital status and nutritional history. The data may also have errors in documenting weight among some measurements.

Conclusion {#s6}
==========

In this study, we have found a linear increment in the BMI of patients with HIV on second-line ART. There was a significant variation in BMI of patients at baseline and through ART treatment time. Duration of treatment, IPT, CPT, functional status, WHO stage of the disease, CD4 count and time interaction of categorical variables like educational status, functional status and WHO stages were found to be significant predictors. The positive change in the BMI of patients shows an encouraging trend because we know this has a positive impact on CD4 recovery, and decreases loss to follow-up and death. Clinicians must also consider the identified risk factors when they provide service to these patients.
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